BIOREM Reports First Quarter Financial Results and Record $68 Million Order Backlog
Financial Summary:
|
Three-months ended |
||
|
|
|
|
( in CDN$'000 except per share data) |
2025 |
2024 |
2024 |
Revenue |
4,730 |
5,918 |
9,316 |
Gross profit |
1,110 |
1,780 |
1,598 |
Operating expenses |
1,016 |
1,264 |
1,250 |
Ebitda* |
229 |
622 |
425 |
Net earnings |
37 |
344 |
194 |
Basic earnings (loss) per share |
0.002 |
0.022 |
0.01 |
Diluted earnings (loss) per share |
0.002 |
0.019 |
0.01 |
*Earnings before interest, taxes and amortization, a non IFRS financial measure |
|
New order bookings in the quarter totaled
Revenues for the first quarter reflected expected seasonal differences in construction schedules and logistical issues experienced by the owner of a large project, which combined to push expected revenues into the second, third and fourth quarters of 2025. Revenues for the quarter totaled
Gross profit in the quarter of
Operating expenses for the quarter were
"Sales initiatives executed in 2024 are now converting into orders in our growing backlog. Bidding activity remains robust and expected to continue throughout the year", said
"One of the key challenges we face is supporting a growing number of international clients that require significant shipping capacity to move our proprietary next generation biological media to their locations. Several current projects require almost 1,000 sea containers in 2025. Securing containers and a berth on vessels on a weekly basis is proving difficult for our customers and we have tasked our logistics team with supporting their efforts in this area."
""We have made significant progress in expanding our service offerings and capabilities. A promising new development is that we have manufactured several on-demand odour control rental units for projects in
During the quarter the Company invested
The Company's cash position stood at
About
SOURCE